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Abstract
The cardiomyocyte phenotypic switch from a proliferative to terminally differentiated state
impacts normal heart development and pathologic myocardial remodeling, yet the signaling
mechanisms that regulate this vital process are incompletely understood. Studies from our lab and
others indicate that focal adhesion kinase (FAK) is a critical regulator of cardiac growth and
remodeling and we found that expression of the endogenous FAK inhibitor, FAK-related non
kinase (FRNK) coincided with postnatal cardiomyocyte arrest. Mis-expression of FRNK in the
embryonic heart led to pre-term lethality associated with reduced cardiomyocyte proliferation and
led us to speculate that the postnatal FRNK surge might be required to promote quiescence in this
growth promoting environment. Herein, we provide strong evidence that endogenous FRNK
contributes to post-mitotic arrest. Depletion of FRNK promoted DNA synthesis in post-natal day
(P) 10 hearts accompanied by a transient increase in DNA content and multi-nucleation by P14,
indicative of DNA replication without cell division. Interestingly, a reduction in tri- and tetra-
nucleated cardiomyocytes, concomitant with an increase in bi-nucleated cells by P21, indicated
the possibility that FRNK-depleted cardiomyocytes underwent eventual cytokinesis. In support of
this conclusion, Aurora B-labeled central spindles (a hallmark of cytokinesis) were observed in
tetra-nucleated P20 FRNK−/− but not wt cardiomyocytes, while no evidence of apoptosis was
observed. Moreover, hearts from FRNK null mice developed ventricular enlargement that
persisted until young adulthood which resulted from myocyte expansion rather than myocyte
hypertrophy or interstitial growth. These data indicate that endogenous FRNK serves an important
role in limiting DNA synthesis and regulating the un-coupling between DNA synthesis and
cytokinesis in the post-natal myocardium.
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While recent evidence suggests that a small subset of mammalian cardiomyocytes retain the
ability to enter the cell cycle throughout their lifespan[1], it is clear that most adult
cardiomyocytes are terminally differentiated and not capable of cell division[2]. This is one
of the primary reasons that myocardial infarction in adult patients results in permanent loss
of muscle mass even after the restoration of blood flow[3]. However, while adult hearts are
notorious for their lack of regenerative capacity, recent studies revealed that injury to hearts
that contain cycling cardiomyocytes (such as zebrafish or newborn mouse hearts) led to
remarkable myocardial regeneration through enhanced myocyte proliferation[4, 5]. These
findings highlight the importance of a clear understanding of myocyte cell cycle regulation,
as targeting cell cycle re-entry could lead to fundamental advancements in the treatment of
cardiac diseases associated with reduced myocyte viability.
Cardiomyocytes are highly proliferative during heart formation in mid-gestation, but their
proliferation slows during the late antenatal period and, within the first 2 weeks following
birth, cardiomyocytes largely lose the capacity to undergo coupled karyo- and cyto-
kinesis[6]. Thus the elevated DNA synthesis that occurs in the neonatal heart, particularly in
the left ventricle following postnatal circulatory pattern switching, results in bi-nucleation
and subsequent cell cycle arrest. In the mouse, this so-called multi-nucleation phase is
completed around 2 weeks after birth. During this same time period cardiomyocytes will
also transition into a hypertrophic growth phase which is responsible for most of the juvenile
cardiac growth[2]. While several studies have defined the positive and negative cell cycle
regulators that influence myocyte proliferation during heart formation[7], less is known
about the signals that regulate the neonatal transition to permanent cell cycle withdrawal.
Several studies indicate that the cardiomyocyte growth state in the developing heart
correlates with regulated shifts in the expression of extracellular matrix and integrin
receptors and the ability of these matrices to support myocyte growth. Indeed, the growth
promoting matrix, fibronectin (FN) is highly expressed in the developing myocardium,
while the growth limiting matrix, collagen I, becomes much more abundant after birth[8].
Moreover, it is clear from prior studies from our laboratory and others that FAK, a critical
mediator of FN-binding integrin receptors, functions to facilitate cardiomyocyte
proliferation during heart formation[9, 10].
FAK activity can be regulated by the expression of its endogenous inhibitor, FRNK.[11, 12]
The FRNK protein is comprised of the carboxyl terminus of FAK (which lacks the catalytic
domain), and FRNK likely functions to limit FAK activity either by direct interaction (since
FAK undergoes dimerization-induced activation)[13] or by competing for FAK’s binding
partners[12, 14]. Interestingly, FRNK transcription results from the utilization of an
alternative start site within the FAK gene that is driven by a distinct promoter embedded
within FAK intronic sequences. We previously showed that whereas FAK expression was
relatively constant during heart development, FRNK was transiently expressed in the heart
with peak levels occurring just prior to neonatal cell cycle withdrawal[15]. Importantly, we
reported that conditional mis-expression of FRNK in the embryonic heart led to peri-natal
lethality associated with impaired cardiomyocyte proliferation and ventricular non-
compaction. Our findings lead us to propose that post-natal expression of cardiac FRNK
might dampen FAK-dependent cardiomyocyte cell cycle progression and facilitate cell cycle
exit. Herein, we report that hearts from FRNK null mice exhibited increased DNA synthesis
and hyperplastic growth into young adulthood, indicating that endogenous FRNK expression
is a major contributor to post-natal cardiomyocyte arrest.
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The FAK, FRNK, phospho-FAK and phospho-Histone H3 antibodies were purchased from
Millipore. Antibodies against Tropomyosin were obtained from Sigma while Aurora B and
Histone H3 antibodies were purchased from AbCam. The cardiac troponin I antibody was
purchased from Thermo, and the N-Cadherin, and GAPDH antibodies were obtained from
Santa Cruz. All Alexa-fluor labeled secondary antibodies as well as Alexa-647 labeled
WGA lectin and Alexa-555 labeled Strepavidin were obtained from Invitrogen. DAPI and
propidium iodine was obtained from Sigma.
Mouse Models
The FRNK−/− mice were obtained from Dr. Tom Parsons and have been previously
described[16]. Mice were genotyped by PCR using previously described primers and DNA
isolated from tail snips.
BrdU Injections
Cardiac cell proliferation was determined by BrdU labeling which was achieved by
administering 40 mg/Kg of BrdU (Sigma) by intraperitoneal injections. The hearts were
harvested 3 days later, fixed, and embedded in paraffin. BrdU incorporation was detected by
using a commercially available kit (Invitrogen) combined with Alexa-555 labeled
strepavidin. Cell proliferation was quantified by scoring the number of BrdU-positive nuclei
per unit area using NIH Image J software.
Myocyte cell isolation and flow cytometry
Ventricular cardiomyocytes were isolated from neonatal mice by trypsin and collagenase
(Worthington) digestion and purified as described previously[15]. After digestion into a
single cell suspension, cells were fixed by dropwise addition of cold 70% ethanol. After
fixation they were resuspended in Hank’s buffered salt solution and stained with propidium
iodide (1:10,000 dilution). In the case of antibody staining with N-Cadherin the cells were
not fixed but were incubated with primary antibody, followed by Alexa 488 labeled
secondary antibody then and washed and permeabilized with Triton-X before propidium
labeling and analysis. All cells were run on an Accuri C6 flow cytometer and analyzed using
Accuri software. For quantification of cardiomyocyte number, the entire population was
counted using the aforementioned method with cardiomyocytes identified by forward and
side scatter properties. For cell staining, after digestion cells were preplated on plastic for 1
hour then were plated on glass chamber slides pretreated with fibronectin or laminin for 2–
24 hours before fixation and staining.
Histological Analysis
Paraformaldehyde fixed, paraffin-embedded hearts were sectioned into 10μm sections,
which were permeabilized with phosphate buffered saline containing 2% bovine albumin
with 0.3% Triton-X and/or 0.1% Saponin (Sigma) and then incubated indicated antibodies
overnight at 1:50–1:200. Secondary antibodies at 1:500–1:2000 dilution were incubated at
room temperature for 1 hour after which slides were washes and sealed with Fluoromount
(Southern Biotech). Cell area measurements were conducted on Alexa-647- WGA Lectin
stained cross sections of the compact zone of the left ventricle using Image J software.
Western Blotting
Tissues were lysed in modified RIPA buffer (50 mM Hepes, 0.15 M NaCl, 2 mM EDTA,
0.1% Nonidet -40, 0.05% sodium deoxycholate, pH7.2) containing 1 mM 4-(2-
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amnionethyl)benzenesulfonyl fluoride hydroxychloride, 0.02 mg/ml aprotonin containing
5% Triton-X. Proteins were boiled in a sample buffer and resolved using SDS-PAGE and
transferred to nitrocellulose. Immunoblotting was performed using a 1:500 dilution of the
appropriate primary antibody with exception of GAPDH which was used 1:1000. Blots were
washed in Tris-buffered saline, pH 7.4 plus 0.05% Triton-X, and blocked in 5% milk,
followed by incubation with the appropriate secondary antibody conjugated to horseradish
peroxidase at 1:2000 dilutions (Sigma). Blots were visualized after incubation with
chemiluminescence reagents (ECL, Thermo). For any reprobing, blots were stripped with
Restore stripping buffer (Thermo) before being washed and restained as described above.
Transthoracic Echocardiography
Echocardiography measurements were taken at the indicated time points using previously
described methods[15]. Briefly, hair was removed from the chest and abdomen, and the
mice were placed on a water-jacketed, warmed table in the left lateral decubitus position for
imaging. A Visualsonic Ultrasound System (Vevo 660) ultrasound machine containing a 30
MHz variable frequency pediatric probe with a 1 cm offset was used to capture
echocardiograms. Standard long axis and short axis M-mode views were recorded when the
mouse possessed a target heart rate between 450 and 650 beats per minute. End diastolic and
end-systolic interventricular septum (IVSd, IVSs), posterior wall thickness (PWTd, PWTs)
and left ventricular internal diameters (LVEDD, LVESD) were calculated and averaged
from three consecutive contractions using Visual Sonics software. All animal use procedures
have been reviewed and approved by the University of North Carolina’s Animal Use and
Care Committee.
Quantification of cardiomyocyte number in serial sections
For extrapolation of total cardiomyocyte number by sectioning and sampling, we utilized a
slight modification of previously reported protocols[17, 18]. First, hearts from 4 week old
mice were fixed in paraformaldehyde as above and dehydrated in methanol. The width and
length of the hearts were measured after dehydration prior to embedding. After embedding,
the hearts were sectioned by digital microtome, with representative 8μm sections taken
every 250μm from the entire heart, with the exception of the extreme ends. The width and
length were also rechecked during this time. The representative sections were then stained to
distinguish cell type and morphology and random areas of the myocardium were imaged
with a confocal microscope. The cells per area were counted using ImageJ software to
compute a myocardial cell density. This density measurement was multiplied by the
calculated heart volume (using both heart weight and heart dimensions) to quantify the
number of cells per heart.
RESULTS
3.1 Hearts from FRNK null mice exhibit sustained post-natal myocyte cycling
We previously reported that endogenous FRNK was expressed in cardiomyocytes derived
from neonatal rat and mouse myocardium[15]. Here, we further defined the duration of post-
natal myocardial FRNK levels by Western blot analysis. As shown in figure 1A, FRNK
levels increased rapidly in the first week of life, with the peak protein levels observed from
postnatal day 7 (P7) through postnatal day 14 (P14). Low levels of FRNK were detected
from postnatal day 21 to 6 weeks post-natal and FRNK was virtually undetectable thereafter.
FAK expression remains relatively steady from the early postnatal period throughout
adulthood in both lines of mice (Fig 1A), but myocardial FAK activity was reproducibly
elevated in neonatal FRNK−/− hearts during the second postnatal week (increased by
approximately 40% at P10 compared to wt). As the timing of FRNK expression correlates
with reported down-regulation of cardiomyocyte DNA synthesis and the uncoupling of
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karyo- and cyto-kinesis[6], we speculated that endogenous FRNK might be involved in
these processes.
FRNK−/− mice were recently generated by homologous recombination-mediated deletion of
a 1-kb fragment that included the FRNK transcriptional start site and 700 bp of upstream fak
intronic sequence. Although these mice were born in the expected Mendelian frequency and
showed no gross phenotype, they have not been specifically examined for alterations in
cardiac growth[16]. To evaluate a role for endogenous FRNK in the control of neonatal
myocyte proliferation, we injected wild type (wt) and FRNK−/− pups with BrdU at P7 and
measured the extent of BrdU incorporation at P10. As shown in Figure 1B and 1C
cardiomyocytes (defined by tropomyosin expression) in FRNK−/− hearts demonstrated a
2.5-fold increase in BrdU uptake compared to wt hearts, while no change in BrdU
incorporation was observed in non-cardiomyocytes. Importantly, no difference in BrdU
staining was observed in the small intestine of FRNK−/− and wt mice (data not shown). This
finding indicates that FRNK functions to selectively limit post-natal myocardial DNA
synthesis.
3.2 Increased Histone Phosphorylation in Cardiomyocytes of FRNK−/− Mice
In order to examine the progression of neonatal cardiomyocytes through the cell cycle, we
interrogated the timing and extent of histone phosphorylation in post-natal wt and FRNK−/−
hearts. Phosphorylation of Histone H3 at the serine-10 residue (pSer10H3) is one of the early
sites of H3 phosphorylation and serves as a useful marker of cells that have completed S
phase and entered G2[19]. Western blot analysis revealed a gradual decline in pSer10H3
levels in wt hearts from P1 to P14 (Fig 2A), whereas pSer10H3 levels were maintained at
higher levels in FRNK−/− hearts. Indeed, pSer10H3 was markedly elevated in P7 and 14
FRNK−/− hearts compared to age-matched controls; time points when FRNK is most highly
expressed in wt hearts. A significant increase in pSer10H3 levels in P10 FRNK−/− hearts
relative to littermate controls was confirmed by immunofluorescence (Fig 2B and D).
Moreover, co-staining with pSer10H3, lectin, and cardiac Troponin revealed that there were
significantly more pSer10H3 positive cardiomyocytes (Fig 2C and E) in FRNK−/− hearts than
littermate controls, while the relative number of pSer10H3 positive non-myocytes (i.e
fibroblasts, smooth muscle cells, endothelial cells; Fig. 2F) was not significantly different.
As expected, given the transient nature of histone phosphorylation, p Ser10H3 positive
cardiomyocytes were less frequent than BrdU positive cells (approximately 1% vs. 10% of
cardiomyocytes in P10 FRNK−/− hearts, respectively). Together these data indicate that
FRNK depletion led to enhanced cardiomyocyte cell cycling from S phase through
interphase.
3.3 Increased Mitosis leads to Cardiomyocyte Polyploidy in FRNK−/− Hearts
Cardiomyocytes are one of a few mammalian cells typically found in a multinucleated state
in healthy adult tissue. At birth, most murine cardiomyocytes are diploid and contain a
single nucleus, but these cells undergo multinucleation (due to uncoupling of mitosis from
cytokinesis) between P4 and P14.[6], Thus adult mouse myocytes are typically tetraploid
(4N) but occasionally can be found in higher levels of multiploidy (6–8N with 2 to 4 nuclei)
[2]. Since we detected increased DNA synthesis in post-natal FRNK−/− hearts, we next
interrogated the extent of karyokinesis (nuclear division), by quantifying cardiomyocyte
nuclei. To this end, we generated single cell suspensions from FRNK−/−, FRNK+/−, and WT
hearts and subjected them to propidium iodide staining followed by flow cytometry (Fig
3A). As shown in figure 3B, at P10 a slight, but significant increase in 6N cells was
observed in FRNK−/− hearts when compared to age-matched littermate controls and by P14,
FRNK−/− hearts contained significantly less 2N cells and significantly more 4N, 6N, and 8N
cells relative to controls (Fig 3C). This change resulted in an approximate 10% increase in
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average DNA content per cell in P14 FRNK−/− hearts relative to age-matched controls. To
establish that the increased polyploidy at P14 was actually due to higher DNA/cell content
in cardiomyocytes, we co-stained cells from P14 FRNK−/− and FRNK−/+ littermate hearts
for N-cadherin prior to subjecting them to flow cytometry. N-cadherin is a transmembrane
adhesion protein present in several cell types, but within the myocardium it is expressed
nearly exclusively in cardiomyocytes[20]. As shown in figure 3E,F, the 4N peak was
predominantly composed of N-cadherin expressing cells (approximately 80% were N-
cadherin positive) whereas the 6N and 8N peaks were exclusively found in the N-Cadherin
positive population; indicating that these peaks largely represent bi-, tri- and tetra-nucleated
cardiomyocytes. Notably, at this timepoint while more 4, 6 and 8N-containing
cardiomyocytes were evident in the FRNK−/− hearts, there was no indication of a greater
proportion of cardiomyocytes. Collectively, these results indicate FRNK depletion led to
increased DNA synthesis which culminated in elevated karyokinesis between P10 and P14.
Interestingly, the increased ploidy observed in post-natal FRNK−/− hearts was transient and
by P21, the extent of multi-nucleation was similar between FRNK null and FRNK
containing hearts (Fig 3D). To determine whether the normalization of polyploidy in the P21
FRNK−/− hearts might have resulted from subsequent cytokinesis, we evaluated the
expression and locale of Aurora B, a protein essential for the progression from mitotic entry
through cytokinesis[21]. Consistent with selective expression of Aurora B in cells
undergoing mitotic division, we found high levels of cardiomyocyte-specific Aurora-B
staining in embryonic mouse hearts (Fig 4A) and lower levels in postnatal hearts (Fig 4B).
However, a significant increase in Aurora-B positive cardiomyocytes were observed in both
P14 and P20 FRNK−/− hearts compared to age-matched controls (Fig 4B–D, and G) in the
absence of elevated DNA synthesis (Fig 4G left). Moreover, when scored for active or
recent cytokinetic events (as defined by the presence of a mitotic spindle- a hallmark of
cytokinesis or 2 closely apposed Aurora B positive cardiomyocyte nuclei), 3.5% of
FRNK−/− cardiomyocytes scored positive in comparison to approximately 1% of wt
cardiomyocytes at P20 (Fig 4H). While we found a similar elevation in Aurora B staining
within FRNK−/− hearts at P14, apparent cytokinesis was more rarely observed at this
timepoint (data not shown). It is important to note that the increased cell cycling associated
with FRNK null hearts in the early neonatal window subsided by this time point. Thus, when
combined with our flow analysis, these findings support the possibility that elevated
cardiomyocyte polyploidy in FRNK null hearts was resolved by subsequent cytokinesis.
3.4 Increased Left Ventricular Mass in FRNK−/− Mice
We next subjected neonatal wt and FRNK−/− mice to serial echocardiograms to assess the
effect of FRNK depletion on cardiac growth. While left ventricular thickness was not
different at week 1, both the interventricular septum and posterior wall were thicker in
FRNK−/− mice by 4 weeks out to 6 weeks of age (the termination of the experiment; Fig 5A,
B and Supplemental Table 1). The total ventricular mass, calculated either by
echocardiography or direct weight measurements, was also significantly increased in
FRNK−/− hearts compared to age-matched controls. (Fig 5C) This finding of significantly
increased ventricular mass/body mass and ventricular mass/tibia length measurements was
corroborated in a second, larger cohort of age- and sex-matched mice sacrificed at 6 weeks
of age (Supplemental Table 2).
In order to determine whether the increased LV wall thickness and mass resulted from
myocyte hypertrophy, hyperplasia or both, we determined the cross-sectional cardiomyocyte
area and the number of cardiomyocytes in FRNK−/− and wt hearts per mm2. As shown in
supplemental figure 1, there was no significant difference in cardiomyocyte size in 6 week
old wt and FRNK−/− hearts. We also examined single cell suspensions of cardiomyocytes
and did not observe a difference in the size of isolated FRNK−/− myocytes compared to wt
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(Supplemental Figure 2). Likewise, there was no significant difference in the total number of
myocytes per unit area of muscle nor in the ratio of myocyte area to interstitial area,
indicating that the observed increase in heart size did not result from an increase in
interstitial or vascular cells. We next strove to quantify total cardiomyocyte number in 4
week post-natal wt and FRNK−/− hearts. To this end, hearts from 4 week old mice were
processed and cardiomyocytes were quantified by 2 distinct methods: completion flow
cytometry and direct counting of random serial sections as reported elsewhere[16, 17]. Both
methodologies revealed a similar increase in the absolute number of cardiomyocytes in
FRNK−/− hearts. As shown in Figure 5D, using flow cytometry we calculated a total of
3.9×106 myocytes per wt ventricle vs. 5.0×106 in FRNK−/−; representing a 28% increase in
cardiomyocytes/ventricle. Using random sampling we calculated 1.7×106 myocytes in wt
ventricle vs. 1.9×106 in FRNK−/−, resulting in a 12% increase (data not shown).
Collectively, these findings indicate that lack of FRNK expression prolonged cardiomyocyte
cell cycle progression in postnatal hearts which culminated in increased total numbers of
cardiomyocytes and larger hearts.
DISCUSSION
FRNK expression in the developing myocardium is restricted to a critical post-natal window
during which cardiomyocytes withdraw from the proliferative cell cycle and undergo bi-
nucleation. We previously reported that mis-expression of FRNK in the embryonic heart led
to pre-term lethality associated with reduced cardiomyocyte proliferation and ventricular
non-compaction[15]. Herein, we provide strong evidence that endogenous FRNK
contributes to post-mitotic arrest, as FRNK−/− hearts exhibited prolonged neonatal cell
cycling and contained larger hearts with more cardiomyocytes than age- and littermate
matched controls.
Based on our previously published report of FRNK expression in the neonatal
myocardium[15], in a pattern inversely correlated with cardiomyocyte proliferation[6], we
speculated that FRNK functioned to promote quiescence in this matrix and growth factor-
rich environment that is positioned to promote high levels of FAK activity. Indeed, hearts
from P10 FRNK−/− mice showed increased numbers of BrdU and pSer10 H3 positive
cardiomyocyte nuclei when compared to age-matched controls, consistent with delayed
cessation of myocyte cell cycling. As expected, the prolonged cell cycling observed in
FRNK−/− hearts was transient, and subsided at about the time when FRNK levels had
markedly dropped in wt hearts (P21). This finding implies that induction of FRNK aids in
restricting post-natal S-phase entry, but that additional mechanisms also regulate cell cycle
withdraw. It is important to note that endogenous FRNK levels subside at time points that
are concurrent with changes in myocardial extracellular matrix deposition that involve a
switch from the growth promoting matrix, fibronectin (a strong FAK activator), to the
growth limiting matrix collagen (a weak FAK activator)[8], although it is formally possible
that FRNK acts to control cardiomyocyte proliferation by a FAK-independent mechanism.
As well, marked changes in cell cycle regulators are observed in this late post-natal window
that certainly contribute to terminal differentiation[22]. Nonetheless, FRNK appears to be
necessary for the rapid transition to post-natal cardiomyocyte quiescence as mitotic activity
was significantly prolonged in FRNK−/− hearts.
Several studies indicate that myocyte bi-nucleation results from a block between karyo- and
cytokinesis that occurs within the first two weeks of postnatal murine heart development[6,
23]. In accordance with these findings, we showed that elevated DNA synthesis in the
FRNK null hearts was coupled with increased DNA content and multi-nucleation by P14,
indicative of DNA replication without cell division. These data indicate that endogenous
FRNK may serve an important role in limiting excess ploidy during the transition stage from
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mono- to bi-nucleated cardiomyocytes. While our data indicated an extra nucleus for every
10 cardiomyocytes on average in FRNK null hearts, we may have underestimated the total
effect of the absence of FRNK given the reports of FAK regulation of N-Cadherin levels[24,
25]. Interestingly, the extent of multi-nucleation in FRNK−/− hearts subsided over time and
levels of tri- and tetra-nucleated myocytes were not significantly different from wt mice by
P21. Thus, cardiomyocytes may have an intrinsic homeostatic mechanism that governs
nuclear number. In fact a precedent exists for this phenomenon. For example, transient
increases in multi-nucleation have been reported to occur in patients following an acute
ischemic insult[3]. Moreover, Wohlschlaeger et al. reported that the polyploidy associated
with failing human hearts was reversed upon mechanical unloading by left ventricular assist
device implantation[26]. As well, studies in a mouse model of sepsis indicated that
cardiomyocyte polyploidy and multi-nucleation increased during the acute phase of severe
infection, but normalized when the infection subsided[27]. While the fate of the multiploid
cells was not fully evaluated in these settings, the study by Wohlschlager et. al. reported that
there was no evidence of apoptosis, indicating that these cells might survive and divide,
consistent with the ultimate outcome of improved tissue health.
The following findings support the likelihood that the transient multi-nucleation observed in
FRNK depleted cardiomyocytes was resolved by cell division: 1) a reduction in tri- and
tetra-nucleated cardiomyocytes and a concomitant increase in bi-nucleated cells occurred in
FRNK−/− hearts between 14 and 21 days post-natal 2) Aurora B-labeled central spindles (a
hallmark of cytokinesis) were observed in tetra-nucleated P20 FRNK−/− but not wt
cardiomyocytes 3) no evidence of increased apoptotic cardiomyocytes was observed in post-
natal FRNK null hearts relative to age-matched controls (as assessed by TUNEL staining;
data not shown) and 4) hearts from FRNK null mice developed ventricular enlargement that
persisted at least until young adulthood and these hearts contained a significantly increased
population of myocytes. Thus, we speculate that deletion of FRNK releases a brake on DNA
synthesis that is followed by increased karyokinesis and eventual cytokinesis. We believe
that the absence of FRNK induces a delay in both the initiation as well as the duration in
cytokinesis, reflected by the observation that Aurora B levels were elevated prior to any
evidence of cell division. The delay in cytokinesis may be a result of failed attempts of
appropriate contractile ring formation that is known to occur in post-natal
cardiomyocytes[28]. Alternatively, since it is unlikely that an appropriately polarized
contractile ring could form in tri-nucleated cells, the lag could reflect the additional time
required for the 2 rounds of DNA synthesis that are necessary to form a tetra-nucleated cell
with cytokinetic potential. We surmise that the increased numbers of multi-ploid cells
undergoing division in P20 FRNK−/− hearts might be a simple reflection of the fact that
nearly 2-fold more tetra-nucleated cells are present in P14 FRNK−/− compared to age-
matched wt hearts. However, it has been suggested that additional cell cycle checkpoints
must be circumvented for cytokinesis to occur in multi-ploid cells[29]. Thus an equally
plausible explanation for our findings is that FRNK might regulate both G1/S- and G2/M-
checkpoint dependent cell cycle withdrawal. While the relative increase in HW observed in
FRNK−/− mice was modest, likely due to the fact that FRNK−/− cardiomyocytes do not
escape eventual cell cycle withdrawal, it was similar to the extent of hyperplastic growth
induced cardiac expression of the potent cell cycle regulator, cMyc[30].
Our studies provide clear evidence that FRNK depletion leads to elevated DNA synthesis in
post-natal hearts that eventually leads to myocyte hyperplasia and cardiac augmentation. In
this regard, FRNK appears to govern tight coupling between DNA synthesis, karyokinesis,
and cytokinesis in the neonatal heart. Although mitosis is a rare event in the adult
myocardium[1], several high profile papers have revealed that myocyte proliferation does
occur following myocardial infarction in both rodent and human hearts[31][32], indicating
that appropriately controlled regeneration of myocytes could be a mechanism to replenish
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lost muscle after a heart attack. Whether FRNK is re-expressed during cardiac disease
progression and whether it functions in a conserved manner to regulate ploidy in the adult
myocardium are important questions for future interrogation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Focal adhesion kinase-related non-kinase (FRNK) limits perinatal cell cycling
• Myocytes from FRNK-null mice exhibit sustained DNA synthesis and transient
polyploidy
• FRNK-null hearts exhibit hyperplastic growth
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Figure 1. Neonatal FRNK null hearts exhibit elevated levels of DNA synthesis
A. Western blot showing temporal expression of FRNK, FAK, and phospho-397 FAK
(pFAK-397) in wild-type mice (Wt) from postnatal day 1 (P1) to 6 weeks (6 wk) and adult
(Ad), with GAPDH shown as loading control. FRNK expression peaks between P7 and P10
while FAK expression remains stable. Far right lanes reveal expected absence of FRNK
protein as well as increased pFAK-397 in P7 and P10 FRNK−/− hearts. FAK activity was
elevated most consistently at P10. B. BrdU incorporation in P10 Wt and FRNK−/− ventricles
was detected by immunofluorescence. BrdU+ cells are red, while DAPI (blue) and cardiac
tropomyosin (green) are shown to distinguish BrdU+ cardiomyocyte (arrows) from non-
cardiomyocytes (arrowheads). C. Quantification of % of BrdU-positive cardiomyocytes
(CM) and non-cardiomyocytes (non-CM) in wt and FRNK−/− hearts (means±SEM; n 4≥
*P<0.01, magnification=600×).
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Figure 2. Depletion of FRNK leads to prolonged postnatal myocyte mitosis
A. Western blot analysis showing relative levels of pSer10histone H3 (pH3) and total histone
H3 (H3) from postnatal Wt and FRNK−/− hearts (collected from 1 day old (P1) to 21 day old
mice (P21). B–F Immunohistochemistry for pH3 in P10 wt and FRNK−/− hearts. (B)
Quantification of total pH3 positive cells/unit area (n=6,7.* - p≤0.05). (C) Quantification of
pH3 positive cardiomyocytes (CM) and non-cardiomyocytes (non-CM) as assessed by co-
staining with cardiac troponin I (n=6,6. *-p≤0.05). (D) Low power immunofluorescent
staining of heart sections for pH3 (red), pH3 positive nuclei indicate by arrows. Scale bar =
1mm. E,F. High power immunofluorescent staining showing pH3 positive cardiomyocyte
(arrow, panel E) and interstitial cell (arrowhead, panel F). Red= pH3. Blue= DAPI. Green=
Troponin I. Scale bar = 10μm.
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Figure 3. FRNK depletion leads to a transient elevation in cardiomyocyte multi-nucleation
A. Representative propidium iodide (PI) staining of cardiac cells showing gating on PI
positive cells (denoted by bracket). B–D. Quantification of relative numbers of 2N, 4N, 6N
and 8N positive cells from wild type (+/+), FRNK +/− (+/−), and FRNK−/− (−/−) hearts at
postnatal day 10, 14 and 21. c′ shows a representative histogram showing relative DNA
content in cells from FRNK−/− (black) and WT (grey) P14 hearts. (Flow experiments
represent at least 2 experiments per data point, n= P10- 6,9,8; P14- 5,9,4; P21- 6,9,8 for wt,
FRNK+/−, and FRNK−/− respectively. *-- p≤0.05 for FRNK−/− vs. both FRNK +/− and WT,
**- p≤0.05 only vs. FRNK +/−, ***- p≤0.05 only vs. WT. E–F. DNA content of N-cadherin
positive (Ncad+) and negative (Ncad−) cells with a scatter plot (F) showing increased DNA
content in Ncad+ cells from FRNK−/− hearts in upper right quadrant. Values represent
pooled samples from 6–7 hearts.
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Figure 4. Nuclear Aurora B signal was maintained in postnatal FRNK−/− hearts
A. Embryonic wt heart showing nearly ubiquitous Aurora B expression in cardiomyocyte
nuclei (arrows). B and C. P 14 wt (B) hearts show diminished Aurora B expression relative
to embryonic hearts and P14 FRNK−/− hearts (C) D–H. Aurora B expression persists in P20
FRNK -/- cardiomyocytes (particularly in those containing enlarged nuclei). Note Aurora B
location along central axis indicative of karyokinesis (left panel). G. Quantification showing
increase in Aurora-B positive cells are not accounted for by prolonged proliferation:
percentages of BrdU positive (left) and Aurora-B positive (right) cardiomyocytes (CM) and
non-cardiomyocytes (NCM) at P20 H. Percentages of Aurora-B positive myocytes at P20
that appeared to be in active or recent cytokinesis based on the pattern of Aurora-B staining.
(Green= tropomyosin, Blue= DAPI, Red= Aurora B, White= WGA lectin; n=4. *-p≤0.01).
Scale bar = 100 microns.
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Figure 5. Postnatal FRNK−/− hearts exhibit ventricular augmentation
A. Echocardiographic measurements of left ventricle (LV) interventricular septum (IVS),
and posterior wall (PW) at 1 and 6 weeks in wt and FRNK−/− mice (n= 7 and 5). B. Time
course of combined (IVS + PW) systolic and diastolic left ventricular wall thickness from
week 1 through week 6. C. LV mass approximated by echo, compared to direct
measurements of heart mass and heart mass adjusted for tibia length. D. Total
cardiomyocytes per heart in 4 week wt and FRNK−/− hearts quantified by flow cytometry
(n=6. *-p≤0.01).
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